oral picomolar & reversible CDK7 inhibitor

Ph. I candidate in breast cancer comb. Therapy

from previous CDK7 inhibitor SY-1365

Journal of Medicinal Chemistry

Syros Pharmaceuticals Inc.

4. The Syros Pharmaceuticals CDK7 kinase inhibitor, SY-5609, is a picomolar, reversible, and highly selective molecule with slow off-rate kinetics.  It follows a prior covalent clinical candidate from Syros. The…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks